CEL SCI CORP
CVMNYSE
$1.17
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↓ -69.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.5M
Enterprise Value
$9.5M
P/E
—
P/S
—
P/B
1.4
EV/EBITDA
—
PEG
—
FCF Yield
-175.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$22.7M
Free Cash Flow (TTM)
-$16.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-330.2%
ROIC
-255.3%
Debt / Equity
—
Net Cash
—
Return 1Y
-71.9%
Company profile
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
- CEO
- Geert R. Kersten
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 43
- Headquarters
- Virginia
- Website
- cel-sci.com
Management & directors
- Kersten Geert RChief Executive Officer
- Prichep Patricia BChief Financial Officer
- Talor EyalChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
CVM Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.67↓ -71.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.0M | -$36.2M | -$36.1M | -$31.5M | -$26.4M | -$24.8M |
| Net income | -$30.3M | -$36.4M | -$36.7M | -$32.4M | -$26.9M | -$25.4M |
| Diluted EPS | -$0.82 | -$0.90 | -$0.87 | -$0.73 | -$15.31 | -$6.27 |
| Operating cash flow | -$15.3M | -$18.8M | -$18.2M | -$22.8M | -$18.8M | -$17.1M |
| Free cash flow | -$17.9M | -$27.8M | -$18.9M | -$23.2M | -$18.9M | -$17.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.7M | -$6.1M | -$6.9M | -$6.4M | -$5.5M | -$6.0M | -$5.4M | -$5.3M |
| Net income | -$6.9M | -$6.1M | -$7.1M | -$6.6M | -$5.7M | -$6.1M | -$5.5M | -$5.5M |
| Diluted EPS | -$4.18 | -$10.85 | -$3.25 | -$2.33 | -$1.36 | $0.67 | -$0.68 | -$0.67 |
| Operating cash flow | -$4.6M | -$4.8M | -$4.1M | -$4.4M | -$3.9M | -$4.7M | -$4.0M | -$4.0M |
| Free cash flow | -$4.6M | -$4.8M | -$4.2M | -$4.4M | -$3.9M | -$4.7M | -$4.0M | -$4.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | KERSTEN GEERT R· Chief Executive Officer | Award | 5,192 | $1.04 | $5,399.68 | filing |
| 2026-06-30 | PRICHEP PATRICIA B· Chief Financial Officer | Award | 4,125 | $1.04 | $4,290.00 | filing |
| 2026-06-30 | TALOR EYAL· Chief Scientific Officer | Award | 2,307 | $1.04 | $2,399.28 | filing |
| 2026-05-14 | KERSTEN GEERT R· Chief Executive Officer | Buy | 300,000 | $1.20 | $360,000.00 | filing |
| 2026-05-13 | KERSTEN GEERT R· Chief Executive Officer | Buy | 100,000 | $1.19 | $119,000.00 | filing |
| 2026-03-31 | KERSTEN GEERT R· Chief Executive Officer | Award | 1,682 | $3.21 | $5,399.22 | filing |
| 2026-03-31 | PRICHEP PATRICIA B· Chief Financial Officer | Award | 1,336 | $3.21 | $4,288.56 | filing |
| 2026-03-31 | TALOR EYAL· Chief Scientific Officer | Award | 747 | $3.21 | $2,397.87 | filing |
| 2026-01-22 | KERSTEN GEERT R· Chief Executive Officer | Buy | 38,023 | $5.26 | $200,000.98 | filing |
| 2025-12-31 | KERSTEN GEERT R· Chief Executive Officer | Award | 998 | $5.26 | $5,249.48 | filing |
| 2025-12-31 | PRICHEP PATRICIA B· Chief Financial Officer | Award | 815 | $5.26 | $4,286.90 | filing |
| 2025-12-31 | TALOR EYAL· Chief Scientific Officer | Award | 456 | $5.26 | $2,398.56 | filing |
| 2025-12-04 | KERSTEN GEERT R· Chief Executive Officer | Buy | 8,389 | $5.96 | $49,998.44 | filing |
| 2025-09-30 | KERSTEN GEERT R· Chief Executive Officer | Award | 570 | $9.20 | $5,244.00 | filing |
| 2025-09-30 | PRICHEP PATRICIA B· Chief Financial Officer | Award | 466 | $9.20 | $4,287.20 | filing |
| 2025-09-30 | TALOR EYAL· Chief Scientific Officer | Award | 260 | $9.20 | $2,392.00 | filing |
| 2025-07-25 | KERSTEN GEERT R· Chief Executive Officer | Buy | 29,197 | $6.85 | $199,999.45 | filing |
| 2025-07-25 | Watson Robert Eugene | Buy | 2,919 | $6.85 | $19,995.15 | filing |
| 2025-06-30 | KERSTEN GEERT R· Chief Executive Officer | Award | 2,292 | $2.29 | $5,248.68 | filing |
| 2025-06-30 | PRICHEP PATRICIA B· Chief Financial Officer | Award | 1,873 | $2.29 | $4,289.17 | filing |
| 2025-06-30 | TALOR EYAL· Chief Scientific Officer | Award | 1,048 | $2.29 | $2,399.92 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.